Skip to Main Content

Author Details

Robert H Carnahan
Vanderbilt University Medical Center
1997
79
29
PMIDPaper TitleJournal TitlePublished Year
36708513Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor.Cell Rep2023
37849399Developing a Prototype Pathogen Plan and Research Priorities for the Alphaviruses.J Infect Dis2023
37516111Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode.Cell Host Microbe2023
37935199SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes.Cell Rep Med2023
37923717Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.Nat Commun2023
37377896Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.Cancer Res Commun2023
37236153A budding new approach strengthens an important message.Cell2023
37029928Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes.Cell Rep2023
37029694Development of a Kinetic ELISA and Reactive B Cell Frequency Assay to Detect Respiratory Syncytial Virus Pre-Fusion F Protein-Specific Immune Responses in Infants.J Pediatric Infect Dis Soc2023
36853802Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus.JCI Insight2023
35297953Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge.J Exp Med2022
35710908Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine.Nat Commun2022
35472136An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer.J Clin Invest2022
35578733Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape.STAR Protoc2022
35857623A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques.Sci Transl Med2022
35780813Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.Chest2022
36516766Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines.Cell Rep2022
35132398A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.Med2022
35076282The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.Sci Transl Med2022
35241839Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.Nat Biotechnol2022
35143767Even old foes can learn sweet new tricks.Cell Host Microbe2022
34901783Standardized two-step testing of antibody activity in COVID-19 convalescent plasma.iScience2022
33259788Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.Cell Host Microbe2021
33532768Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail.bioRxiv2021
33691139Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.Cell2021
33501445Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.bioRxiv2021
34411541Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.Cell Rep2021
34437301Human antibody recognition of H7N9 influenza virus HA following natural infection.JCI Insight2021
34548634Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.Nat Microbiol2021
34715022Pan-ebolavirus protective therapy by two multifunctional human antibodies.Cell2021
34416147Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress.Cell2021
34592170Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.Cell Rep2021
34100018Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking.bioRxiv2021
34341788Single-Cell Profiling of the Antigen-Specific Response to BNT162b2 SARS-CoV-2 RNA Vaccine.bioRxiv2021
34056628Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.Cell Rep Med2021
33972937Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.bioRxiv2021
33472939Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques.J Virol2021
33097605A requirement for p120-catenin in the metastasis of invasive ductal breast cancer.J Cell Sci2021
32511409Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.bioRxiv2020
32023489Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.Immunity2020
33229516Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions.Proc Natl Acad Sci U S A2020
33028979Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19.Nat Immunol2020
33398272Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection.bioRxiv2020
33398266Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions.bioRxiv2020
33301709Human Antibodies Protect against Aerosolized Eastern Equine Encephalitis Virus Infection.Cell2020
32747832Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics.Nat Biomed Eng2020
32935107Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.bioRxiv2020
32695842Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection.Mol Ther Methods Clin Dev2020
32668443Potently neutralizing and protective human antibodies against SARS-CoV-2.Nature2020
32749241Anti-influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface.J Clin Invest2020
  • 1 - 50 of 79

Recommended Authors

Mir M Khalid
Gladstone Institutes
Career Start Year 2016
Number of shared co-authors 3
Taha Y Taha
Gladstone Institutes
Career Start Year 2015
Number of shared co-authors 1
Megan Lo
University of San Diego
Career Start Year 2015
Number of shared co-authors 3
Yi Shi
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Career Start Year 2014
Number of shared co-authors 0
Aaron L Oom
New York University Grossman School of Medicine
Career Start Year 2014
Number of shared co-authors 2
Nicholas Dambrauskas
Center for Global Infectious Disease Research, Seattle Children's Research Institute
Career Start Year 2013
Number of shared co-authors 0
Jonathan Diep
Amgen Inc.
Career Start Year 2012
Number of shared co-authors 0
Thiago Y Oliveira
The Rockefeller University
Career Start Year 2010
Number of shared co-authors 2
Craig B Wilen
Yale School of Medicine
Career Start Year 2010
Number of shared co-authors 4
Thomas J Gardner
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 0
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 2
Peter C Fridy
The Rockefeller University
Career Start Year 2007
Number of shared co-authors 0
Aaron M Ring
Yale University School of Medicine
Career Start Year 2006
Number of shared co-authors 0
David Noah Sather
Center for Global Infectious Disease Research, Seattle Children's Hospital
Career Start Year 2005
Number of shared co-authors 1
Sunil Thomas
Lankenau Institute for Medical Research
Career Start Year 2004
Number of shared co-authors 2
Chen Xu
University of Massachusetts Chan Medical School
Career Start Year 2003
Number of shared co-authors 0
Ning Jiang
The University of Texas at Austin
Career Start Year 2000
Number of shared co-authors 0
Renee C Ireton
Center for Innate Immunity and Immune Disease, University of Washington
Career Start Year 1997
Number of shared co-authors 1
Vladimir Vigdorovich
Center for Global Infectious Disease Research, Seattle Children's Hospital
Career Start Year 1997
Number of shared co-authors 0
Benhur Lee
Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 4
Yu-Tsueng Liu
University of California San Diego
Career Start Year 1994
Number of shared co-authors 0
Ande West
University of North Carolina at Chapel Hill
Career Start Year 1993
Number of shared co-authors 8
Zhiqiang An
Zhengzhou University
Career Start Year 1992
Number of shared co-authors 4
Pierre Leblanc
McLean Hospital and Program in Neuroscience, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 0
Amy S Espeseth
Merck & Co., Inc.
Career Start Year 1989
Number of shared co-authors 0
Garry P Nolan
Stanford University School of Medicine
Career Start Year 1985
Number of shared co-authors 3
Leslie Lobel
Ben-Gurion University of the Negev
Career Start Year 1984
Number of shared co-authors 1
Jos?? Ignacio Casal
Max-Planck-Institut fur Entwicklungsbiologie
Career Start Year 1984
Number of shared co-authors 0
Richard H Scheuermann
J. Craig Venter Institute
Career Start Year 1983
Number of shared co-authors 3
Martin S Zand
University of Rochester Medical Center
Career Start Year 1983
Number of shared co-authors 3

Collaborators

James E Crowe
Vanderbilt University Medical Center
Co-authored papers 51
Pavlo Gilchuk
Vanderbilt University Medical Center
Co-authored papers 22
Michael S Diamond
Washington University School of Medicine
Co-authored papers 21
Rita E Chen
Co-authored papers 13
Ivelin S Georgiev
Co-authored papers 10
Ralph S Baric
University of North Carolina
Co-authored papers 7
Larissa B Thackray
Washington University School of Medicine
Co-authored papers 6
Dan H Barouch
Co-authored papers 5
Jason S McLellan
Co-authored papers 5
Galit Alter
Co-authored papers 4
Alexandra Sch??fer
University of North Carolina at Chapel Hill
Co-authored papers 4
Laura A VanBlargan
Washington University School of Medicine
Co-authored papers 4
Ted M Ross
Center for Vaccines and Immunology, University of Georgia
Co-authored papers 3
Barton F Haynes
Co-authored papers 3
Jens Meiler
Vanderbilt University
Co-authored papers 3
Mark R Denison
Vanderbilt University Medical Center
Co-authored papers 3
William B Klimstra
Co-authored papers 3
Isaac P Thomsen
Vanderbilt University Medical Center
Co-authored papers 3
Natalia A Kuzmina
University of Texas Medical Branch, USA Galveston National Laboratory
Co-authored papers 3
Jill M Pulley
Vanderbilt University School of Medicine
Co-authored papers 2
Lisa E Gralinski
University of North Carolina at Chapel Hill
Co-authored papers 2
Gordon R Bernard
Vanderbilt University
Co-authored papers 2
Laura J Stevens
Vanderbilt University Medical Center
Co-authored papers 2
James Logue
Center for Pathogen Research, University of Maryland School of Medicine
Co-authored papers 2
Melanie D Ohi
Co-authored papers 2
Julie A Bastarache
Vanderbilt University Medical Center
Co-authored papers 2
Stuart Weston
University of Maryland School of Medicine
Co-authored papers 2
Adrianus C M Boon
Co-authored papers 2
Allison P Wheeler
Vanderbilt University Medical Center
Co-authored papers 2
Todd W Rice
Vanderbilt University Medical Center
Co-authored papers 2
Release 1.2